skip to content
  1. Home
  2. >
  3. Questions
  4. >
  5. CSU: I have recently acquired shares of Constellation Software and done some reading about this company. [Constellation Software Inc.]
You can view 2 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I have recently acquired shares of Constellation Software and done some reading about this company. I looked at it a number of years ago and didn't buy it because of the "frightening" P/E ratio. Every time I looked at it or read analysts reports about it they would say the same thing "great company with terrific growth but too expensive. Wait for a better entry point. We can see how that has turned out. 10 years ago it was trading at about $130 now it's $2700. There is an article in the globe today about Topicus. To paraphrase it says that Topicus is the size CSU was 10 years ago and looks good but it's too expensive.
Is there a good reason to think that there might be an opportunity here that I missed 10 years ago with CSU?
Thanks for your ever helpful insight!
Asked by Richard on May 03, 2023
5i Research Answer:

It is true that P/E has not been a reliable metric to measure the CSU group’s valuation. Mainly because their primary growth engines come from acquisitions, which they have been able to deploy the majority of their cash flow each year to pursue growth. As a result, amortization expense (accounting for M&A) would account for the majority of total expenses, the earnings would be understated, and the stock always appear to be expensive.

We think investors can look at metrics such as EV/EBITDA, or Price/Free Cash Flow to have a better picture of the valuation. Currently:
CSU’s EV/EBITDA multiple is 33.0x
TOI’s EV/EBITDA multiple is 37.0x
(based on total shares outstanding of 129,841,819 and EBITDA converted from EUR to $321M CDN)
Although TOI is trading at a higher valuation compared to CSU, TOI’s organic growth (around 6%-8%) and total growth (expected around 25% for the near future) is impressive. We think TOI’s premium valuation makes sense given its growth prospects. For these types of compounders, investors can average into the position over time. Trading can be thin, but over time we think they are going to work out very well.